These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30028196)

  • 21. Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model.
    Sugiura H; Matsushita A; Futaya M; Teraoka A; Akiyama KI; Usui N; Nagano N; Nitta K; Tsuchiya K
    PLoS One; 2018; 13(3):e0191706. PubMed ID: 29518087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
    Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans.
    Hanudel MR; Eisenga MF; Rappaport M; Chua K; Qiao B; Jung G; Gabayan V; Gales B; Ramos G; de Jong MA; van Zanden JJ; de Borst MH; Bakker SJL; Nemeth E; Salusky IB; Gaillard CAJM; Ganz T
    Nephrol Dial Transplant; 2019 Dec; 34(12):2057-2065. PubMed ID: 30007314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coronary microvascular dysfunction in the setting of chronic ischemia is independent of arginase activity.
    Sodha NR; Boodhwani M; Clements RT; Feng J; Xu SH; Sellke FW
    Microvasc Res; 2008 Mar; 75(2):238-46. PubMed ID: 17707069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired NO-mediated vasodilatation in rat coronary arteries after asphyxial cardiac arrest.
    Troelsen TT; Granfeldt A; Secher N; Tønnesen EK; Simonsen U
    Acta Anaesthesiol Scand; 2015 May; 59(5):654-67. PubMed ID: 25881833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGF23 and Klotho in chronic kidney disease.
    Olauson H; Larsson TE
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):397-404. PubMed ID: 23666415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart.
    Quyyumi AA; Dakak N; Andrews NP; Gilligan DM; Panza JA; Cannon RO
    Circulation; 1995 Aug; 92(3):320-6. PubMed ID: 7634444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGF23: a mature renal and cardiovascular risk factor?
    Zoccali C; Yilmaz MI; Mallamaci F
    Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease.
    Singh S; Grabner A; Yanucil C; Schramm K; Czaya B; Krick S; Czaja MJ; Bartz R; Abraham R; Di Marco GS; Brand M; Wolf M; Faul C
    Kidney Int; 2016 Nov; 90(5):985-996. PubMed ID: 27457912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.
    David V; Martin A; Isakova T; Spaulding C; Qi L; Ramirez V; Zumbrennen-Bullough KB; Sun CC; Lin HY; Babitt JL; Wolf M
    Kidney Int; 2016 Jan; 89(1):135-46. PubMed ID: 26535997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation.
    Egli-Spichtig D; Imenez Silva PH; Glaudemans B; Gehring N; Bettoni C; Zhang MYH; Pastor-Arroyo EM; Schönenberger D; Rajski M; Hoogewijs D; Knauf F; Misselwitz B; Frey-Wagner I; Rogler G; Ackermann D; Ponte B; Pruijm M; Leichtle A; Fiedler GM; Bochud M; Ballotta V; Hofmann S; Perwad F; Föller M; Lang F; Wenger RH; Frew I; Wagner CA
    Kidney Int; 2019 Oct; 96(4):890-905. PubMed ID: 31301888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of NO-mediated Relaxing Effects in the Thoracic Aorta in an Experimental Chronic Kidney Disease Mouse Model.
    Mori-Kawabe M; Yasuda Y; Ito M; Matsuo S
    J Atheroscler Thromb; 2015 Aug; 22(8):845-53. PubMed ID: 25740549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldosterone impairs coronary adenosine-mediated vasodilation via reduced functional expression of Ca
    Khan M; Meuth AI; Brown SM; Chandrasekar B; Bowles DK; Bender SB
    Am J Physiol Heart Circ Physiol; 2019 Aug; 317(2):H357-H363. PubMed ID: 31199187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carbamylated low-density lipoprotein induces endothelial dysfunction.
    Speer T; Owala FO; Holy EW; Zewinger S; Frenzel FL; Stähli BE; Razavi M; Triem S; Cvija H; Rohrer L; Seiler S; Heine GH; Jankowski V; Jankowski J; Camici GG; Akhmedov A; Fliser D; Lüscher TF; Tanner FC
    Eur Heart J; 2014 Nov; 35(43):3021-32. PubMed ID: 24658767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium.
    Six I; Okazaki H; Gross P; Cagnard J; Boudot C; Maizel J; Drueke TB; Massy ZA
    PLoS One; 2014; 9(4):e93423. PubMed ID: 24695641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGF23 signaling impairs neutrophil recruitment and host defense during CKD.
    Rossaint J; Oehmichen J; Van Aken H; Reuter S; Pavenstädt HJ; Meersch M; Unruh M; Zarbock A
    J Clin Invest; 2016 Mar; 126(3):962-74. PubMed ID: 26878171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammation both increases and causes resistance to FGF23 in normal and uremic rats.
    Rodríguez-Ortiz ME; Díaz-Tocados JM; Muñoz-Castañeda JR; Herencia C; Pineda C; Martínez-Moreno JM; Montes de Oca A; López-Baltanás R; Alcalá-Díaz J; Ortiz A; Aguilera-Tejero E; Felsenfeld A; Rodríguez M; Almadén Y
    Clin Sci (Lond); 2020 Jan; 134(1):15-32. PubMed ID: 31860056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Klotho and endocrine fibroblast growth factors: markers of chronic kidney disease progression and cardiovascular complications?
    Kuro-O M
    Nephrol Dial Transplant; 2019 Jan; 34(1):15-21. PubMed ID: 29800324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on fibroblast growth factor 23 in chronic kidney disease.
    Wolf M
    Kidney Int; 2012 Oct; 82(7):737-47. PubMed ID: 22622492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strength of Fibroblast Growth Factor 23 as a Cardiovascular Risk Predictor in Chronic Kidney Disease Weaken by ProBNP Adjustment.
    Emrich IE; Brandenburg V; Sellier AB; Schauerte J; Wiedenroth J; Untersteller K; Lennartz CS; Seiler-Mussler S; Wagenpfeil S; Fliser D; Heine GH
    Am J Nephrol; 2019; 49(3):203-211. PubMed ID: 30808827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.